BioMarin expects Alesta acquisition to cut full-year 2026 GAAP, non-GAAP diluted EPS by about $1.55

PUBT · 1d ago
BioMarin expects Alesta acquisition to cut full-year 2026 GAAP, non-GAAP diluted EPS by about $1.55
  • BioMarin expects the Alesta acquisition to drive about USD 320 million of total pre-tax charges in full-year 2026.
  • Forecast includes about USD 283 million of acquired IPR&D expense in Q3 2026, completed Aug. 31, 2026.
  • Full-year charges seen cutting GAAP diluted EPS by about USD 1.55, same impact expected for non-GAAP diluted EPS.
  • Q3 impact estimated at about USD 1.50 per share on both GAAP diluted EPS, non-GAAP diluted EPS.
  • Updated full-year 2026 guidance planned with third-quarter results; prior Aug. 6 outlook excluded Alesta.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001048477-26-000019), on October 06, 2026, and is solely responsible for the information contained therein.